Mechanistically, the reduction of Foxa1 expression has been associated with several pathological phenotypic features of NAFLD, including induction of triglyceride synthesis and accumulation, inhibition of fatty acid β-oxidation, and homocysteinemia [29–31]. This evidence concerns the gene FOXA1 and metabolic dysfunction-associated steatotic liver disease.